Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-135-5 | CAS number: 7440-25-7
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- genetic toxicity in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- Not reported
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Depleted Uranium Health Effects: Transformation, Mutagenicity, and Carcinogenicity
- Author:
- Miller AC
- Year:
- 1 998
- Bibliographic source:
- AFRRI Special Publication 98-3: 11-13
- Reference Type:
- publication
- Title:
- Health Effects of Depleted Uranium Fragments
- Author:
- Armed Forces Radiobiology Research Institute
- Year:
- 1 998
- Bibliographic source:
- Livengood DR (ed) An Armed Forces Radiobiology Research Institute Workshop
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Studies with depleted uranium embedded animals were reviewed to help assess the risk for carcinogenesis and mutagenesis from depleted uranium embedded fragments. Animals with tantalum embedded fragments served as a control.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Tantalum
- EC Number:
- 231-135-5
- EC Name:
- Tantalum
- Cas Number:
- 7440-25-7
- Molecular formula:
- Ta
- IUPAC Name:
- tantalum
- Test material form:
- not specified
- Details on test material:
- - Name of test material (as cited in study report): tantalum implants
Constituent 1
Results and discussion
Any other information on results incl. tables
Studies with depleted uranium embedded animals demonstrated that increased tissue uranium content was associated with aberrant activation of several of the oncogenes and tumour suppressor genes associated with preneoplastic lesions and human carcinogenesis. Specific point mutations in these genes have also been identified. In contrast, tissues from animals with tantalum implants did not show this aberrant oncogene pattern. Oncoproteins and tumour suppressor proteins were also found in the serum of animals with depleted uranium pellets. These proteins were not detected in serum from animals implanted with tantalum.
Applicant's summary and conclusion
- Conclusions:
- Tissues from animals with tantalum implants did not show an aberrant oncogene pattern. Oncoproteins and tumour suppressor proteins were not detected in serum from animals implanted with tantalum.
- Executive summary:
Studies to help assess the risk for carcinogenesis and mutagenesis from depleted uranium embedded fragments were conducted, with tantalum serving as a control. The studies with depleted uranium embedded animals demonstrated that increased tissue uranium content was associated with aberrant activation of several of the oncogenes and tumour suppressor genes associated with preneoplastic lesions and human carcinogenesis. Specific point mutations in these genes were also identified. In contrast, tissues from animals with tantalum implants did not show this aberrant oncogene pattern. Oncoproteins and tumour suppressor proteins were also found in the serum of animals with depleted uranium pellets. These proteins were not detected in serum from animals implanted with tantalum.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
